Mammary Cell News 10.18 May 9, 2018 | |
| |
TOP STORYPromoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element Investigators showed that the PVT1 promoter has a tumor-suppressor function that is independent of PVT1 lncRNA. CRISPR interference of PVT1 promoter enhanced breast cancer cell competition and growth in vivo. [Cell] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors showed that whilst estrogen receptor-positive adenomyoepitheliomas display PIK3CA or AKT1 activating mutations, estrogen receptor-negative adenomyoepitheliomas harbor highly recurrent codon Q61 HRAS hotspot mutations, which co-occur with PIK3CA or PIK3R1 mutations. [Nat Commun] Full Article Scientists identified that zoledronic acid (ZA), a marketed drug for treating osteoporosis and bone metastasis, is a direct inhibitor of urine diphosphate–galactose ceramide galactosyltransferase (UGT8), which blocks the sulfatide biosynthetic pathway. Significantly, a clinically achievable dosage of ZA exhibited apparent inhibitory effect on migration, invasion, and lung metastasis of basal-like breast cancer cells. [J Exp Med] Full Article | Press Release Investigators showed that the popultation of aldehyde dehydrogenase (ALDH)-positive cells in a mouse 4T1 breast tumor model exhibits pronounced circadian alterations. Alterations in the number of ALDH-positive cells was generated by time-dependent increases and decreases in the expression of Aldh3a1. [Cancer Res] Abstract | Full Article Researchers performed in vitro assays in breast cancer cell lines, and the results indicated that DCLRE1B, MRPS30, and ATG10 played a vital role in breast tumorigenesis via certain disruption of cell behaviors. [Am J Hum Genet] Abstract | Press Release Intermittent Hypoxia Induces a Metastatic Phenotype in Breast Cancer The authors showed that exposing mammary tumor cells to intermittent hypoxia promoted clonal diversity, upregulated metastasis-associated gene expression, induced a pro-tumorigenic secretory profile, increased stem-like cell marker expression, and gave rise to tumor-initiating cells at a relatively higher frequency. [Oncogene] Abstract Fibroblast-Derived CXCL12 Promotes Breast Cancer Metastasis by Facilitating Tumor Cell Intravasation Investigators generated a novel conditional allele of Cxcl12 in mice and used a fibroblast-specific Cre transgene along with various mammary tumor models to evaluate CXCL12 function in the breast cancer metastasis. [Oncogene] Abstract Interference of YAP nuclear translocation using the statin cerivastatin reversed the upregulation of interleukin 6 and the pro-invasive effect of retinoic acid on MDA-MB-231 breast cancer cells and also decreased invasion and viability of MDA-MB-468 breast cancer cells. [Sci Rep] Full Article Researchers exposed an organotypic mammary model consisting of a collagen-embedded duct structure lined with MCF7 cells to 17-β estradiol, with and without human mammary fibroblasts in the surrounding matrix. MCF7 cells grown as ductal structures were polarized and proliferated at rates comparable to in vivo breast tissue. [Sci Rep] Full Article Despite no changes in mammosphere formation, 0.25μM cadmium inhibited branching organoid formation in hydrogels by 73%. RNA-seq revealed cadmium downregulated genes associated with extracellular matrix formation and epithelial-mesenchymal transition, while upregulating genes associated with metal response including metallothioneins and zinc transporters. [Toxicol Sci] Abstract Catalytic Double Cyclization Process for Antitumor Agents against Breast Cancer Cell Lines The compounds, 6,6a-dihydrofuro[3,2-b]furan-2(5H)-ones, had significant antiproliferative activity in vitro on human breast cancer cell lines, both hormone-receptor positive (MCF-7) and triple negative (TNBC; MDA-MB-231 and MDAMB-468), while exhibiting practically no effects on normal MCF-10A (human mammary epithelial) and 3T3-L1 (murine fibroblasts) cells. [iScience] Abstract | Full Article | Graphical Abstract | |
| |
REVIEWSGenetic Modifiers of the Breast Tumor Microenvironment Research indicates that breast cancer risk modifiers directly impact cancer cells, yet it is equally plausible that some modifier alleles impact the nonmalignant tumor microenvironment (TME). The authors examine the list of current breast cancer candidate genes that may modify breast cancer risk and outcome through the TME. [Trends Cancer] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSOncoSec Medical Incorporated (OncoSec), has entered a clinical trial collaboration and supply agreement with Merck to evaluate the combination of OncoSec’s ImmunoPulse® IL-12 with Merck’s anti-PD-1 therapy KEYTRUDA® in a Phase II clinical trial. [OncoSec Medical Incorporated] Press Release NANOBIOTIX, announced that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3’s mechanism of action. [NANOBIOTIX] Press Release Lynparza® (Olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer AstraZeneca announced that Health Canada has approved Lynparza® tablets, as a monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. [AstraZeneca] Press Release | |
| |
POLICY NEWSHarassment Should Count as Scientific Misconduct Research culture and policies are quick to denounce plagiarism, data fabrication and mismanagement of funds, yet we have too long ignored the mistreatment of people. Science is a social endeavor; ignoring harassment perpetuates a culture in which people who experience or witness hostile behaviors are afraid to speak up, cannot do their best work, or leave science altogether. [Nature News] Editorial Australian Budget Delivers for Science Facilities and Medical Research The government will push to invest almost Aus$1.9 billion (US$1.4 billion) over the next 12 years in shared research infrastructure — such as microscopes, supercomputers, a marine observing system and telescopes used in myriad disciplines, from nanotechnology to oceanography. Medical research will receive an increase of $1.3 billion, to be spent on various programs and initiatives over 10 years that improve health and boost the medical industry, including $500 million for a genomics and precision-medicine initiative. [Nature News] Editorial Animal Tests Surge under New U.S. Chemical Safety Law The cause of the increase isn’t clear. But the new law imposes stricter requirements on a broader array of chemicals than its predecessor, including both new products and ones already on the market, and experts say Environmental Protection Agency staff may be trying to comply by gathering more test data from companies. [ScienceInsider] Editorial Basic Scientists Still Feel Pinch of New NIH Clinical Trial Policy Basic researchers who study the brain and human behavior thought lawmakers had come to their rescue in March by blocking the National Institutes of Health (NIH) from redefining their studies as clinical trials. But NIH officials are still pushing ahead with new requirements that scientists say make no sense and will cripple their research. [ScienceInsider] Editorial Petition Asks National Academy of Sciences to Boot Sexual Harassers An online petition calling on the National Academy of Sciences to revoke memberships bestowed on people sanctioned for sexual harassment has garnered more than 250 signatures since it was posted. [The Scientist] Editorial FDA Moves to Stop Rogue Clinics From Using Unapproved Stem Cell Therapies The U.S. Stem Cell Clinic marketed stem cell products to patients without FDA approval and “while violating current good manufacturing practice requirements, including some that could impact the sterility of their products, putting patients at risk,’ the FDA said in a statement. The agency said it was acting because the U.S. Stem Cell Clinic did not address violations outlined in a warning letter from the FDA last August. [The New York Times Company] Editorial
| |
EVENTSNEW 2018 National Cancer Research Institute (NCRI) Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Position – Breast Cancer Research (Rutgers Cancer Institute of New Jersey) Project Manager – DCIS PRECISION Project (Netherlands Cancer Institute) Graduate Student – Breast and Colorectal Cancer (Dalhousie University) Postdoctoral Fellows – Breast Cancer Stem Cell Research (New York University School of Medicine) Postdoctoral Fellowship – Cancer Research (Mass General Hospital/Harvard Medical School) Postdoctoral Fellow – Breast Cancer Research (Northwestern University) Postdoctoral Researcher – Breast Cancer (Baylor College of Medicine) Senior Research Technician – Breast Cancer (Baylor College of Medicine) Research Technician – Breast Cancer (Baylor College of Medicine) Postdoctoral Fellow – Cancer Research (Indiana Uniersity School of Medicine) Postdoctoral Fellows – Molecular and Translational Cancer Biology (Thomas Jefferson University) Tenure Track Faculty Position – Cancer Research (University of Alabama at Birmingham) Postdoctoral Researcher – Breast Cancer (UT Southwestern Medical Center) Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine) Staff Position – Breast Cancer Tumor Immunology (Cleveland Clinic Taussig Cancer Institute) Research Fellow – Breast Cancer (Dana-Farber Cancer Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|